

In the claims:

Please amend the claims as follows:

1-7. (Canceled)

8. (Currently amended) ~~An~~ A composition comprising at least 70% biologically active receptor-immunoglobulin fusion protein (receptor-Ig-fusion protein), obtained by culturing a mammalian host cell transformed with DNA encoding the receptor-Ig fusion protein in a culture system having a ~~low~~ temperature of about 27° C to about 35° C, wherein the receptor-Ig fusion protein comprises a member of the TNF family of receptors.

9. (Canceled)

10. (Currently amended) ~~The Ig-fusion protein composition of claim 8, comprising~~ wherein the receptor-Ig-fusion protein comprises lymphotoxin- $\beta$  LT- $\beta$  receptor (LT- $\beta$ -R)-Ig fusion protein.

11. (Currently amended) ~~The Ig-fusion protein composition of claim 8, comprising~~ wherein the receptor-Ig-fusion protein comprises herpes virus entry mediator (HVEM)-Ig-fusion protein.

12-15. (Canceled)

16. (Currently amended) A pharmaceutical preparation obtained by

- (a) culturing a host transformed with DNA encoding ~~an~~ a receptor-Ig-fusion protein in a culture system having a ~~low~~ temperature of about 27° C to about 32 ° C, wherein the receptor-Ig fusion protein comprises a member of the TNF family of receptors, thereby expressing biologically active receptor-Ig-fusion proteins;
- (b) recovering biologically active receptor-Ig-fusion proteins from said culture system;

and

(c) combining the biologically active receptor-Ig-fusion proteins of step (b) with a pharmaceutically acceptable carrier.

17. (Canceled)

18. (Currently amended) The pharmaceutical preparation of claim 16 ~~17~~ wherein the receptor-Ig-fusion protein comprises a LT- $\beta$ -R-Ig-fusion protein ~~lymphotoxin- $\beta$  receptor~~.

19. (Currently amended) The pharmaceutical preparation of claim 16 ~~17~~ wherein the receptor-Ig-fusion protein comprises an HVEM-Ig fusion protein.

20-25. (Canceled)

26. (Currently amended) ~~An~~ A composition comprising a biologically active receptor-Ig-fusion protein obtained by culturing yeast transformed with DNA encoding the receptor-Ig-fusion protein in a culture system having a ~~low~~ temperature of about 10° C to about 25 ° C.

27. (Currently amended) The receptor-Ig-fusion protein of claim 26 comprising a member of the TNF family of receptors.

28. (Currently amended) The receptor-Ig-fusion protein of claim 27 comprising LT- $\beta$ -R-Ig-fusion protein ~~LT  $\beta$  receptor, or a fragment thereof~~.

29. (Currently amended) The receptor-Ig-fusion protein of claim 27 ~~26~~ comprising HVEM-Ig-fusion protein ~~or a fragment thereof~~.

30-36. (Canceled)

37. **(New)** A composition comprising biologically active HVEM-Ig-fusion proteins obtained by culturing a mammalian host cell transformed with DNA encoding the HVEM-Ig-fusion protein in a culture system having a temperature of about 27° C to about 35 ° C.
38. **(New)** The composition of claim 37, wherein the culture system has a temperature of about 27° C to about 32 ° C.
39. **(New)** The composition of any one of claims 8, 10, and 11, wherein the culture system has a temperature of about 27° C to about 32 ° C.